PF-06863135, also called PF-3135 or elranatamab, is a bispecific humanized mAb (IgG2a), which targets BCMA on MM cells and CD3 on T cells and subsequently causes T-cell-mediated lysis of myeloma cells [101]. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.